AZN - AstraZeneca PLC

NYSE - NYSE Delayed Price. Currency in USD
44.34
+0.16 (+0.36%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close44.18
Open44.36
Bid44.36 x 1300
Ask44.37 x 1300
Day's Range44.29 - 44.55
52 Week Range35.30 - 45.28
Volume1,484,534
Avg. Volume2,968,468
Market Cap114.792B
Beta (3Y Monthly)0.48
PE Ratio (TTM)51.80
EPS (TTM)0.86
Earnings DateN/A
Forward Dividend & Yield1.40 (3.17%)
Ex-Dividend Date2019-08-08
1y Target Est46.14
Trade prices are not sourced from all markets
  • Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY
    Zacks

    Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY

    FDA approves Roche's (RHHBY) tumor-agnostic medicine, Rozlytrek, J&J's Sirturo for young TB patients.

  • AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL
    Zacks

    AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL

    The Breakthrough Therapy Designation (BTD) to AstraZeneca's (AZN) Calquence is based on positive interim data from two phase III studies.

  • Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC
    Zacks

    Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC

    Roche's (RHHBY) lung cancer portfolio gets a boost with the approval of yet another drug, Rozlytrek, for metastatic NSCLC.

  • Agios Rides High on Tibsovo Sales Amid Acute Competition
    Zacks

    Agios Rides High on Tibsovo Sales Amid Acute Competition

    Agios' (AGIO) wholly owned precision medicine Tibsovo is picking up sales since its approval and strong sequential growth delivered in Q2. Undue reliance on Celgene for royalties is a constant worry.

  • Merck's Cancer Immunotherapy Keytruda Continues to Aid Growth
    Zacks

    Merck's Cancer Immunotherapy Keytruda Continues to Aid Growth

    Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.

  • 3 Healthcare Stocks at All-Time Highs: Are They Buys?
    Motley Fool

    3 Healthcare Stocks at All-Time Highs: Are They Buys?

    They're flying high right now. But are these three healthcare stocks smart picks?

  • Business Wire

    CALQUENCE® (acalabrutinib) Granted US Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia

    Designation based on positive results from two Phase III trials

  • Business Wire

    LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer

    AstraZeneca and Merck’s LYNPARZA when added to standard-of-care bevacizumab significantly increased the time women lived without disease progression or death

  • Benzinga

    AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis

    Last week, AstraZeneca plc (NYSE: AZN) reported positive results for its prostrate cancer treatment Lynparza for patients with certain genetic profiles. Ahmad wrote in a note on Tuesday that AstraZeneca’s incremental success changes the game for Clovis.

  • Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises
    Zacks

    Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises

    Spectrum Pharma (SPPI) beats bottom-line estimates in the second quarter.

  • Reuters

    No-deal Brexit could deepen Europe's shortage of medicines - experts

    As the Oct. 31 deadline for Britain to leave the European Union approaches, health professionals are warning that shortages of some medicines could worsen in Europe in the event of a no-deal Brexit. Britain's food and drink lobby warned last week that the country would experience shortages of some fresh foods if there is a disorderly no-deal Brexit.

  • AVEO Pharmaceuticals (AVEO) Q2 Earnings Beat, Revenues Lag
    Zacks

    AVEO Pharmaceuticals (AVEO) Q2 Earnings Beat, Revenues Lag

    AVEO Pharmaceuticals' (AVEO) loss is narrower than expected in the second quarter of 2019. However, revenues fall short of estimates.

  • Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates
    Zacks

    Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates

    Inovio Pharmaceuticals (INO) disappoints with earnings and revenue miss in the second quarter. Shares depreciate in after-hours trading.

  • Business Wire

    TAGRISSO® (OSIMERTINIB) Significantly Improves Overall Survival in the Phase III FLAURA Trial for 1st-line EGFR-mutated Non-small Cell Lung Cancer

    TAGRISSO is the only medicine demonstrating statistically-significant overall survival benefit in this setting. AstraZeneca today announced positive overall survival (OS) results from the Phase III FLAURA trial, a randomized, double-blinded, multicenter trial of TAGRISSO in previously-untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) mutations.

  • GlobeNewswire

    Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer

    SALT LAKE CITY, Aug. 07, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, today announced that the.

  • Business Wire

    LYNPARZA® (Olaparib) Phase III Profound Trial in HRR* Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint

    AstraZeneca and Merck’s LYNPARZA Met the Primary Endpoint of Significantly Increasing the Time Patients Selected for BRCA1/2 or ATM Mutations Live Without Radiographic Disease Progression vs.

  • The CEO Who Capped a $37 Billion Recovery With a Cancer Drug Deal
    Bloomberg

    The CEO Who Capped a $37 Billion Recovery With a Cancer Drug Deal

    (Bloomberg) -- The future looked bleak for Japanese drugmaker Daiichi Sankyo Co. when George Nakayama took over as chief executive officer in 2010.The stock was in the middle of a six-year free fall, its Indian subsidiary Ranbaxy Laboratories Ltd. was banned by the U.S. from selling products there, and a new anti-clotting medicine was slapped with the strictest safety warning.Nakayama, a former salesman for one of Japan’s biggest brewers, decided to reboot Daiichi Sankyo, pivoting away from generic medicines and toward the more lucrative business of cancer drugs. He sold scandal-ridden Ranbaxy for $3.2 billion, acquired two U.S.-based makers of cancer medicines and focused research on a class of drugs that could replace chemotherapy.Affirmation arrived in March, when British drugmaker AstraZeneca Plc agreed to pay as much as $6.9 billion to jointly develop one of those medicines, known as antibody drug conjugates, for patients of breast and other cancers. Under Nakayama’s turnaround plan, Daiichi Sankyo’s stock has rocketed 470% to an all-time high -- adding $37 billion in market value to make it Japan’s second-biggest drugmaker after Takeda Pharmaceutical Co.“So many things happened, but I was extremely lucky,” Nakayama, 69, said during a July 12 interview. “Looking back, it was a pretty tough start. It got better over time.”Soon after the deal, Nakayama ceded the CEO title to Sunao Manabe, a veterinarian by training, though Nakayama remains chairman. He’s leaving on a high note, with Daiichi Sankyo the best performer this year on an MSCI index of the biggest drugmakers. The stock climbed 0.7% to a fresh record on Tuesday, while Japan’s benchmark Topix index fell 0.4%.Analysts say the future looks bright for the Tokyo-based company, formed in 2005 through the merger of Daiichi Pharmaceutical Co. and Sankyo Co. Revenue is expected to increase 14% through 2023, while operating profit is seen surging 78%, according to analysts surveyed by Bloomberg.“The strategy shift is now starting to pay off,” said Yasuhiro Nakazawa, an analyst at SMBC Nikko Securities Inc. in Tokyo. “Daiichi Sankyo is really betting on the new direction as a whole.”That blueprint is anchored by the cancer drug known as DS-8201, which the company plans to seek U.S. approval for by Sept. 30. Daiwa Securities Co. analyst Kazuaki Hashiguchi predicts it will reach almost $8 billion in annual sales by 2030, surpassing Roche Holding AG’s breast-cancer drug Herceptin, which DS-8201 seeks to replace.The drug’s potential as a blockbuster medicine comes as global pharmaceutical giants are scrambling to transform themselves to replace aging pipelines. Cancer has become one of the hottest areas for deal activity between drug and biotechnology companies, as scientific advances are leading to new tailored therapies with strong growth potential.Daiichi Sankyo partnered with AstraZeneca to develop and commercialize DS-8201, and the two companies agreed to split profit and costs. Such ADCs are a class of drugs that can attack cancer cells in the body without damaging surrounding healthy ones. Analysts say DS-8201 could triple the number of patients who receive targeted treatment for breast cancer, which kills more than 500,000 women annually.“This Daiichi Sankyo drug has the potential to transform cancer care, so it is a very important product for us and, of course, for our partner,” Pascal Soriot, CEO of AstraZeneca, said in a July 25 interview on Bloomberg Television.Daiichi Sankyo is developing about a dozen cancer-fighting compounds, and considering further partnerships. It will devote a “significant portion” of its research budget toward successfully bringing them to the market, Manabe said in a July 9 interview. “Compared with a few years ago, our cancer pipeline is very rich now,” Manabe said.This new focus represents a sea change for Daiichi Sankyo, which was saddled with headaches when Nakayama took over. His early priority was to save Ranbaxy’s operations. Two of the Indian company’s four plants faced U.S. bans because of data fabrication, so Nakayama tried to strengthen the remaining two. His efforts fizzled, and they were banned by the U.S. starting in 2013.“We just couldn’t quite grasp the depth of Ranbaxy’s data falsification,” Nakayama said.Daiichi Sankyo found a buyer in Indian rival Sun Pharmaceutical Industries Ltd. in 2014. But its problems weren’t over. Daiichi Sankyo paid a $39 million fine in 2015 to settle U.S. allegations it gave kickbacks to doctors in exchange for prescribing company medicines. Most of the alleged infractions occurred before Nakayama’s tenure. That same year, its blood thinner edoxaban received U.S. approval but carried a “boxed warning” about use by certain patients, limiting its market potential.Shifting FocusNakayama decided the company needed a change, so he sold the Sun Pharmaceutical stake and shifted his focus to cancer drugs, overhauling operations, making acquisitions and hiring Antoine Yver, who ran the oncology unit at AstraZeneca, in April 2016.Daiichi Sankyo previously spent more than $1 billion to gain cancer medicines through takeovers of Plexxikon Inc. in 2011 and Ambit Biosciences Corp. in 2014, and its ADCs were showing promise in early testing.“The global oncology market became subdivided and not a single winner could take it all,” Nakayama said. “If we had the world-class science and acted fast, we had a chance.”The former CEO also takes a humble view of the company’s turnaround, giving some credit to fortune: in finding a buyer for Ranbaxy, having labs produce new compounds at the right time, latching onto AstraZeneca’s Yver to run the cancer business.“God made the timing well,” Nakayama said.To contact the reporters on this story: Kanoko Matsuyama in Tokyo at kmatsuyama2@bloomberg.net;Grace Huang in Tokyo at xhuang66@bloomberg.netTo contact the editors responsible for this story: Rachel Chang at wchang98@bloomberg.net, Michael Tighe, Jeff SutherlandFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • 3 Lung Cancer Stocks That Could Soar in September
    Motley Fool

    3 Lung Cancer Stocks That Could Soar in September

    These industry giants could make big moves after this year's World Conference on Lung Cancer.

  • It Might Be Better To Avoid AstraZeneca PLC's (LON:AZN) Upcoming 1.0% Dividend
    Simply Wall St.

    It Might Be Better To Avoid AstraZeneca PLC's (LON:AZN) Upcoming 1.0% Dividend

    AstraZeneca PLC (LON:AZN) is about to trade ex-dividend in the next 3 days. Ex-dividend means that investors that...

  • Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates
    Zacks

    Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates

    Ironwood (IRWD) beats on earnings and sales in the second quarter. Demand for Linzess remains strong.

  • Merck (MRK) Beats on Q2 Earnings & Sales, Raises '19 View
    Zacks

    Merck (MRK) Beats on Q2 Earnings & Sales, Raises '19 View

    Merck (MRK) beats estimates for earnings as well as sales in second-quarter 2019. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand. Shares up.

  • Thomson Reuters StreetEvents

    Edited Transcript of AZN.L earnings conference call or presentation 25-Jul-19 11:00am GMT

    Q2 2019 AstraZeneca PLC Earnings Call

  • 10 Biggest Cancer-Fighting Stocks
    Motley Fool

    10 Biggest Cancer-Fighting Stocks

    The fight against cancer is a big battle. And these 10 companies are among the biggest combatants you can invest in.

  • AstraZeneca (AZN) Jumps: Stock Rises 5.7%
    Zacks

    AstraZeneca (AZN) Jumps: Stock Rises 5.7%

    AstraZeneca (AZN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

  • Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment
    Zacks

    Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment

    AstraZeneca (AZN), Roche (RHHBY), Bristol-Myers (BMY) and Glaxo (GSK) report Q2 results. FDA approves Lilly's (LLY) nasal glucagon to treat severe hypoglycemia.